156 related articles for article (PubMed ID: 11986953)
1. N-(4-hydroxyphenyl)retinamide increases ceramide and is cytotoxic to acute lymphoblastic leukemia cell lines, but not to non-malignant lymphocytes.
O'Donnell PH; Guo WX; Reynolds CP; Maurer BJ
Leukemia; 2002 May; 16(5):902-10. PubMed ID: 11986953
[TBL] [Abstract][Full Text] [Related]
2. Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators.
Batra S; Reynolds CP; Maurer BJ
Cancer Res; 2004 Aug; 64(15):5415-24. PubMed ID: 15289350
[TBL] [Abstract][Full Text] [Related]
3. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism.
Maurer BJ; Melton L; Billups C; Cabot MC; Reynolds CP
J Natl Cancer Inst; 2000 Dec; 92(23):1897-909. PubMed ID: 11106681
[TBL] [Abstract][Full Text] [Related]
4. N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase.
Wang H; Maurer BJ; Reynolds CP; Cabot MC
Cancer Res; 2001 Jul; 61(13):5102-5. PubMed ID: 11431347
[TBL] [Abstract][Full Text] [Related]
5. Dynamics of ceramide generation and metabolism in response to fenretinide--Diversity within and among leukemia.
Morad SA; Davis TS; Kester M; Loughran TP; Cabot MC
Leuk Res; 2015 Oct; 39(10):1071-8. PubMed ID: 26220867
[TBL] [Abstract][Full Text] [Related]
6. Human T-cell lymphotropic virus type I-transformed T-cells have a partial defect in ceramide synthesis in response to N-(4-hydroxyphenyl)retinamide.
Darwiche N; Abou-Lteif G; Najdi T; Kozhaya L; Tayoun AA; Bazarbachi A; Dbaibo GS
Biochem J; 2005 Nov; 392(Pt 1):231-9. PubMed ID: 16086670
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.
Kang MH; Wan Z; Kang YH; Sposto R; Reynolds CP
J Natl Cancer Inst; 2008 Apr; 100(8):580-95. PubMed ID: 18398104
[TBL] [Abstract][Full Text] [Related]
8. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines.
Maurer BJ; Metelitsa LS; Seeger RC; Cabot MC; Reynolds CP
J Natl Cancer Inst; 1999 Jul; 91(13):1138-46. PubMed ID: 10393722
[TBL] [Abstract][Full Text] [Related]
9. 4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines.
Villani MG; Appierto V; Cavadini E; Bettiga A; Prinetti A; Clagett-Dame M; Curley RW; Formelli F
Cancer Res; 2006 Mar; 66(6):3238-47. PubMed ID: 16540676
[TBL] [Abstract][Full Text] [Related]
10. Hypoxia-mediated fenretinide (4-HPR) resistance in childhood acute lymphoblastic leukemia cells.
Yang B; Fan L; Fang L; He Q
Cancer Chemother Pharmacol; 2006 Oct; 58(4):540-6. PubMed ID: 16520989
[TBL] [Abstract][Full Text] [Related]
11. Ceramide signaling in fenretinide-induced endothelial cell apoptosis.
Erdreich-Epstein A; Tran LB; Bowman NN; Wang H; Cabot MC; Durden DL; Vlckova J; Reynolds CP; Stins MF; Groshen S; Millard M
J Biol Chem; 2002 Dec; 277(51):49531-7. PubMed ID: 12388538
[TBL] [Abstract][Full Text] [Related]
12. N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL).
Faderl S; Lotan R; Kantarjian HM; Harris D; Van Q; Estrov Z
Leuk Res; 2003 Mar; 27(3):259-66. PubMed ID: 12537979
[TBL] [Abstract][Full Text] [Related]
13. N-(4-hydroxyphenyl)retinamide induces growth arrest and apoptosis in HTLV-I-transformed cells.
Darwiche N; Hatoum A; Dbaibo G; Kadara H; Nasr R; Abou-Lteif G; Bazzi R; Hermine O; de Thé H; Bazarbachi A
Leukemia; 2004 Mar; 18(3):607-15. PubMed ID: 14712289
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of bioactive sphingolipids in 4-HPR-resistant leukemia cells.
Apraiz A; Idkowiak-Baldys JK; Boyano MD; Pérez-Yarza G; Hannun YA; Asumendi A
BMC Cancer; 2011 Nov; 11():477. PubMed ID: 22061047
[TBL] [Abstract][Full Text] [Related]
15. Increasing intracellular ceramide: an approach that enhances the cytotoxic response in prostate cancer cells.
Wang H; Charles AG; Frankel AJ; Cabot MC
Urology; 2003 May; 61(5):1047-52. PubMed ID: 12736045
[TBL] [Abstract][Full Text] [Related]
16. N-(4-Hydroxyphenyl)retinamide increases dihydroceramide and synergizes with dimethylsphingosine to enhance cancer cell killing.
Wang H; Maurer BJ; Liu YY; Wang E; Allegood JC; Kelly S; Symolon H; Liu Y; Merrill AH; Gouazé-Andersson V; Yu JY; Giuliano AE; Cabot MC
Mol Cancer Ther; 2008 Sep; 7(9):2967-76. PubMed ID: 18790777
[TBL] [Abstract][Full Text] [Related]
17. Ceramide synthesis and metabolism as a target for cancer therapy.
Reynolds CP; Maurer BJ; Kolesnick RN
Cancer Lett; 2004 Apr; 206(2):169-80. PubMed ID: 15013522
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic responses to N-(4-hydroxyphenyl)retinamide in human pancreatic cancer cells.
Messner MC; Cabot MC
Cancer Chemother Pharmacol; 2011 Aug; 68(2):477-87. PubMed ID: 21072519
[TBL] [Abstract][Full Text] [Related]
19. 4-HPR-mediated leukemia cell cytotoxicity is triggered by ceramide-induced mitochondrial oxidative stress and is regulated downstream by Bcl-2.
Morales MC; Pérez-Yarza G; Rementería NN; Boyano MD; Apraiz A; Gómez-Muñoz A; Pérez-Andrés E; Asumendi A
Free Radic Res; 2007 May; 41(5):591-601. PubMed ID: 17454142
[TBL] [Abstract][Full Text] [Related]
20. Synergistic effects of the fenretinide (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells.
Shan D; Gopal AK; Press OW
Clin Cancer Res; 2001 Aug; 7(8):2490-5. PubMed ID: 11489831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
